Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Identifying Drugs for the Treatment of Spinocerebellar Ataxia Type 2 (SCA2)
Movement Disorders
(-)
171
Authors/Disclosures
Daniel R. Scoles, PhD, FÂé¶¹´«Ã½Ó³»­ (University of Utah) The institution of Dr. Scoles has received research support from NIH.
No disclosure on file
Stefan M. Pulst, MD, FÂé¶¹´«Ã½Ó³»­ (University of Utah) Dr. Pulst has received personal compensation in the range of $500-$4,999 for serving as a Consultant for venrock. Dr. Pulst has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arrowhead. Dr. Pulst has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Leverna. Dr. Pulst has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Âé¶¹´«Ã½Ó³»­. Dr. Pulst has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Leninthal LLC. The institution of Dr. Pulst has received research support from NINDS. Dr. Pulst has received intellectual property interests from a discovery or technology relating to health care.
Kevin E. Chapman, MD (Barrow Neurological Institute at Phoenix Children's Hospital) No disclosure on file